Meeting Overview | We are pleased to invite you to our satellite symposium, titled Evaluating the Current Therapeutic Landscape for Advanced Prostate Cancer, to be held on 17 October 2011 at the 31st Congress of Société Internationale D’Urologie in Berlin, Germany. |
Date and Location | 17 October 2011
16.45 – 18.00 hrs
Room: Stockholm
ICC Berlin
Neue Kantstrasse
Berlin, Germany |
Target Audience | This educational activity is specifically designed for medical and surgical oncologists, urologists, radiologists, and other healthcare providers interested and/or involved in the treatment of patients with prostate cancer. |
Learning Objectives | Upon completion of this activity participants should be able to:
- Identify areas of unmet need in the treatment of patients with advanced prostate cancer
- Evaluate newly approved therapies for the treatment of advanced prostate cancer and how to effectively incorporate these agents into the standard of care
- Examine the rationale, efficacy, and safety of novel therapies under investigation for advanced prostate cancer, including emerging targeted therapies, immunotherapies, and chemotherapeutic agents
- Discuss the importance of multidisciplinary treatment strategies in the care of patients with advanced prostate cancer
|
Faculty | Chair
Cora Sternberg, MD, FACP
San Camillo Forlanini Hospital
Rome, Italy
Faculty
Karim Fizazi, MD, PhD
Institut Gustave Roussy
Villejuif, France
Peter Mulders, MD, PhD
University Medical Center Nijmegen
Nijmegen, the Netherlands
Thomas Powles, MD
St Bartholomew’s Hospital
London, United Kingdom |
Agenda |
| 16.45 |
|
Welcome and introduction
Cora Sternberg, MD, FACP |
| 16.50 |
|
Examining the issues and unmet needs in the treatment of advanced prostate cancer
Cora Sternberg, MD, FACP |
| 17.05 |
|
Integration of newly approved therapies into the continuum of care for advanced prostate cancer
Thomas Powles, MD |
| 17.25 |
|
What are the promising novel strategies on the horizon in advanced prostate cancer?
Karim Fizazi, MD, PhD |
| 17.45 |
|
Importance of the multidisciplinary team in prostate cancer: The urologist's perspective
Peter Mulders, MD, PhD |
| 18.00 |
|
Concluding remarks and adjournment
Cora Sternberg, MD, FACP |
|
|
|
|
Organizer | This meeting is a prIME Oncology activity.
|
Support | Support for this educational activity has been provided by Dendreon Corporation.
|
|
